The Influence of −174 G/C Interleukin 6 Promoter Gene Polymorphism to Interleukin 6 Concentration in the End Stage Renal Disease Patients with Dialysis: A Single-center Experience in Indonesia

Authors

  • Riri Andri Muzasti Division of Nephrology and Hypertension, Department of Internal Medicine, Universitas Sumatera Utara, Medan, Indonesia
  • Herman Hariman Deparment of Clinical Pathology, Universitas Sumatera Utara, Medan, Indonesia
  • Elvita Rahmi Daulay Departement of Radiology, Universitas Sumatera Utara, Medan, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2020.4715

Keywords:

Interleukin-6, Gene, ESRD

Abstract

BACKGROUND: Chronic kidney disease (CKD) is classified as a multifactorial disease as a combination of genetic and environmental factors that affect the onset and progression of end-stage renal disease (ESRD). In the last decades are recognized that inflammation, where the critical modulator is cytokines, can occur before the onset of kidney disease and can be a causative factor in the development of CKD. Interleukin (IL)-6 has several polymorphisms in the promoter region, such as 174 G-C, 634 C-G, 572 G-C, and 597 G-A. G/C single nucleotide polymorphism of the IL-6 gene at position 174 in the promoter region is reported to affect the level of IL-6 expression. Unfortunately, there is a lack of data about the genotype frequencies of -174 G/C IL-6 promoter gene polymorphism in Indonesian with ESRD.

AIM: This study aimed to analyze whether −174 G/C IL-6 promoter gene polymorphism influences the concentration of IL-6 in ESRD patients with dialysis in Indonesia.

METHODS: We recruited 95 outpatients who were undergoing regular hemodialysis for ≥3 months at the Rasyida Renal Hospital, Medan, in this cross-sectional study. IL-6 genotype polymorphism was analyzed using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique. The enzyme-linked immunosorbent assay method was performed to assess the quantitative IL-6 serum.

RESULTS: PCR-RFLP examination showed the frequency distribution of the IL-6 genotype -174 G/C gene; 72 (75.8%) respondents had GG genotypes; 22.1% of respondents had the CG genotype, and (2.1%) had the CC genotypes. Patients with the CC genotype were statistically significant to have higher IL-6 concentration compared to other genotypes (p < 0.001). Likewise, with diabetic patients, statistics showed higher IL-6 concentration compared to non-diabetics patients (p < 0.001).

CONCLUSION: This is the first study showing that -174 G/C IL-6 promoter gene polymorphism influences the IL-6 concentrations in ESRD patients with dialysis in Indonesia. Multicenter studies are needed to validate these findings.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Prodjosudjadi W, Suhardjono A. End-stage renal disease in Indonesia: Treatment development. Ethn Dis. 2009;19(1):33. PMid:19484872

Yang H, Lu K, Lee H, Huang S, Lin Y, Wu C, et al. Role of the functional toll-like receptor-9 promoter polymorphism (-1237T/C) in increased risk of end-stage renal disease: A case-control study. PLoS One. 2013;8(3):e58444. https://doi.org/10.1371/ journal.pone.0058444 PMid: 23472199

Rao M, Wong C, Kanetsky P, Girndt M, Stenvinkel P, Reilly M, et al. Cytokine gene polymorphism and progression of renal and cardiovascular diseases. Kidney Int. 2007;72(5):549-56. https:// doi.org/10.1038/sj.ki.5002391 PMid:17579660

Shanmuganathan R, Ramanathan K, Padmanabhan G, Vijayaraghavan B. Evaluation of interleukin 8 gene polymorphism for predicting inflammation in Indian chronic kidney disease and peritoneal dialysis patients. Alex J Med. 2017;53(3):215-20. https://doi.org/10.1016/j.ajme.2016.06.004

Buraczynska M, Jozwiak L, Ksiazek P, Borowicz E, Mierzicki P. Interleukin-6 gene polymorphism and faster progression to end-stage renal failure in chronic glomerulonephritis. Transl Res. 2007;150(2):101-5. https://doi.org/10.1016/j.trsl.2007.03.003

Suliman ME, Stenvinkel P. Contribution of inflammation to vascular disease in chronic kidney disease patients. Saudi J Kidney Dis Transpl. 2008;19(3):329-45. PMid:18445891

Aker S, Bantis C, Reis P, Kuhr N, Schwandt C, Grabensee B, et al. Influence of interleukin-6G-174C gene polymorphism on coronary artery disease, cardiovascular complications, and mortality in dialysis patients. Nephrol Dial Transplant. 2009;24(9):2847-51. https://doi.org/10.1093/ndt/gfp141

Ng DP, Nurbaya S, Ye SH, Krolewski AS. An IL-6 haplotype on human chromosome 7p21 confers risk for impaired renal function in Type 2 diabetic patients. Kidney Int. 2008;74(4):521- 7. https://doi.org/10.1038/ki.2008.202 PMid:18496509

Ranganath P, Tripathi G, Sharma RK, Sankhwar SN, Agrawal S. Role of non-HLA genetic variants in end-stage renal disease. Tissue Antigens. 2009;74(2):147-55. https://doi. org/10.1111/j.1399-0039.2009.01276.x PMid:19497039

Buckham TA, McKnight AJ, Benevente D, Courtney AE, Patterson CC, Simmonds M. Evaluation of five interleukin genes for association with end-stage renal disease in white Europeans. Am J Nephrol. 2010;32(2):103-8. https://doi. org/10.1159/000314943 PMid:20551628

Kandil MH, Magour GM, Khalil GI, Maharem DA, Nomair AM. Possible association of interleukin-1beta (-511C/T) and interleukin-6 (-174G/C) gene polymorphisms with atherosclerosis in end-stage renal disease Egyptian patients on maintenance hemodialysis. Egypt J Med Hum Genet. 2013;14(3):267-75. https://doi.org/10.1016/j.ejmhg.2013.04.001

Jančić I, Arsenović-Ranin N, Šefik-Bukilica M, Živojinović S, Damjanov N, Spasovski V, et al. -174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis. Rheumatol Int. 2012;33(6):1481-6. https://doi.org/10.1007/s00296-012-2586-y PMid:23233117

Su H, Lei C, Zhang C. Interleukin-6 signaling pathway and its role in kidney disease: An update. Front Immunol. 2017;8:405. https://doi.org/10.3389/fimmu.2017.00405 PMid:28484449

Beberashvili I, Sinuani I, Azar I, Yasur H, Shapiro G, Feldman L, et al. IL-6 levels, nutritional status, and mortality in prevalent hemodialysis patients. Clin J Am Soc Nephrol. 2011;6(9):2253- 63. https://doi.org/10.2215/cjn.01770211 PMid:21852667

Downloads

Published

2020-08-20

How to Cite

1.
Muzasti RA, Hariman H, Daulay ER. The Influence of −174 G/C Interleukin 6 Promoter Gene Polymorphism to Interleukin 6 Concentration in the End Stage Renal Disease Patients with Dialysis: A Single-center Experience in Indonesia. Open Access Maced J Med Sci [Internet]. 2020 Aug. 20 [cited 2022 Jul. 1];8(A):563-6. Available from: https://oamjms.eu/index.php/mjms/article/view/4715

Most read articles by the same author(s)

1 2 > >>